Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 16;15(1):104.
doi: 10.1186/s13048-022-01037-6.

The clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review

Xin Wang #  1   2 , Shiyuan Wang #  1 , Shujuan Yao #  2 , Wei Shi  3 , Ke Ma  4
Affiliations

The clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review

Xin Wang et al. J Ovarian Res. .

Abstract

Background: Ovarian malignant mesoderm mixed tumor (OMMMT) is a rare clinical entity. To provide reference for the treatment and prognosis of OMMMT, we analyzed the clinical features, pathology and molecular biology characteristic of published cases.

Methods: The English and Chinese reported cases of OMMMT were selected from PubMed, Clinical Trials.gov and CNKI database from 2000 to December 15th, 2021 following the PRISMA guidelines.

Results: A total of 63 literatures including 199 OMMMT cases were included. The average age of patients at diagnosis was 56.46 years, the highest incidence age was 60-65 years, and 82% of them were menopausal women. Most patients were diagnosed in FIGO III stage (59.64%). The most common symptom of OMMMT was abdominal pain (60.5%). 61.6% of patients were accompanied by ascites, while ascites was not associated with metastatic tumor and local recurrence. The CA125 of 88.68% patients increased. The most common reported carcinomatous component and sarcomatous component were serous adenocarcinoma (44.96%) and chondrosarcoma (24.81%), respectively. Initial treatment included surgery (94.97%) and taxanes-based (55.10%) or platinum-based (85.71%) chemotherapy regimens. The median survival time of patients was 20 months. Heterologous sarcoma component did not shorten life expectancy. The optimal ovarian tumor cell debulking surgery (OOTCDS), radiotherapy and chemotherapy could significantly prolong the median survival time of patients. Furthermore, platinum drugs could significantly prolong the survival time after comparing various chemotherapy schemes. Besides, the combination of platinum and taxanes was therapeutically superior to the combination of platinum and biological alkylating agents.

Conclusion: The OOTCDS and platinum-based chemotherapy regimen can improve the prognosis of OMMMT. Targeted therapy might become a new research direction in the future. Since the elderly patients are the majority, the toxicity of new drugs on the elderly patients is more noteworthy.

Keywords: Clinical; Ovarian malignant mesoderm mixed tumor; Pathology; Prognosis; Treatment.

PubMed Disclaimer

Conflict of interest statement

All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Screening process of included articles in the research
Fig. 2
Fig. 2
A Proportion of countries; B The age distribution of patients
Fig. 3
Fig. 3
The KM Analysis of Chemotherapy Efficacy. A Platinum; B Taxanes; C Bioalkylating Agengts; D Anthracene Ring; E Platinum+ Taxanes; F Platinum+ Bioalkylating Agengts
Fig. 4
Fig. 4
The KM Analysis of influencing factors. A Stage; B Sarcoma component; C Surgical modality; D Radiotherapy or chemotherapy
Fig. 5
Fig. 5
The Correlation Analysis of influencing factors. A Stage; B Sarcoma component; C Surgical modality; D Radiotherapy or chemotherapy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–236. doi: 10.3322/caac.20121. - DOI - PubMed
    1. Menon S, Deodhar K, Rekhi B, Dhake R, Gupta S, Ghosh J, et al. Clinico-pathological spectrum of primary ovarian malignant mixed mullerian tumors (OMMMT) from a tertiary cancer institute: a series of 27 cases. Indian J Pathol Microbiol. 2013;56(4):365–371. doi: 10.4103/0377-4929.125293. - DOI - PubMed
    1. Schipf A, Mayr D, Kirchner T, Diebold J. Molecular genetic aberrations of ovarian and uterine carcinosarcomas--a CGH and FISH study. Virchows Arch. 2008;452(3):259–268. doi: 10.1007/s00428-007-0557-6. - DOI - PubMed
    1. Cantrell LA, Van Le L. Carcinosarcoma of the ovary a review. Obstet Gynecol Surv. 2009;64(10):673–680. doi: 10.1097/OGX.0b013e3181b8aff3. - DOI - PubMed
    1. Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S55–S60. doi: 10.1097/IGC.0000000000000228. - DOI - PubMed

Publication types